MC
ACHN

Marcus Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Marcus Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-69,400
Closed -$1.75M – 51
2017
Q1 		$1.75M Sell
69,400
-30,600
-31% -$127K 1.63% 30
2016
Q4 		$413K Buy
100,000
+25,000
+33% +$133K 0.45% 45
2016
Q3 		$608K Buy
+75,000
New +$638K 0.58% 45

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Marcus Capital's ACHN Position: Q2 2017 in Review

Marcus Capital sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 69,400 shares — an estimated $1.75M sold.

Marcus Capital first reported a position in ACHN in Q3 2016 and held it in 3 quarters. The position peaked at $1.75M in Q1 2017. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

  • Marcus Capital reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Marcus Capital sold 69,400 Achillion Pharmaceuticals shares in Q2 2017, an estimated $1.75M.
  • Marcus Capital first reported a position in Achillion Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Marcus Capital's Achillion Pharmaceuticals position peaked at $1.75M in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on Marcus Capital's 13F filing for Q2 2017, filed 10 Aug 2017.